Objective-To examine the impact of low-density lipoprotein (LDL), an established mediator of atherosclerosis, on the transcription factor cAMP-response element-binding protein (CREB), which is a regulator of vascular smooth muscle cell (VSMC) quiescence. Methods and Results-VSMC CREB content is diminished in rodent models of diabetes and pulmonary hypertension. We examined aortic CREB content in rodent models of aging, hypertension, and insulin resistance, and we determined nuclear CREB protein in the medial VSMC of high-fat-fed LDL receptor-null mice. There was significant loss of CREB protein in all models. In vitro, primary culture rat aortic VSMC exposed to LDL and oxidized LDL exhibited a rapid, transient increase in CREB phosphorylation and transient phosphorylation/activation of Akt, ERK, JNK, ans p38 MAPK. Exposure to oxidized LDL, but not to LDL, for 24 to 48 hours decreased CREB protein in a dose-dependent fashion and led to nuclear exclusion of CREB. Pharmacological reactive oxygen species scavengers and inhibition of ERK activation blocked oxidized LDL-mediated CREB downregulation. Conclusion-These data support a model wherein loss of VSMC CREB protein, which renders these cells more susceptible to activation and apoptosis, is a common pathological response to vascular injury and potentially contributes to plaque progression. (Arterioscler Thromb Vasc Biol. 2010;30:733-741.)
A therosclerosis is the leading cause of death in the Western world (http://www.cdc.gov/nchs-National). In the past few decades much has been learned about cardiovascular risk factors and their impact on the development of atherosclerotic plaque. The current theoretical model of atherogenesis includes a complex interplay between endothelial cells, vascular smooth muscle cells (VSMC), circulating inflammatory cells, and the vascular adventitia. 1, 2 The end result is a proinflammatory microenvironment that promotes a vicious cycle of plaque progression. Interruption of this cycle is necessary to slow atherosclerosis progression and stabilize existing plaque. Medications that lower low-density lipoprotein (LDL) cholesterol have revolutionized therapy for cardiovascular disease but do not fully normalize cardiovascular risk. 3 Our laboratory has identified the transcription factor cAMP-response element-binding protein (CREB) as a modulator of smooth muscle cell phenotype. CREB blunts mitogen-stimulated VSMC proliferation, migration, and matrix protein expression, and it protects smooth muscle cells from apoptosis. 4 -6 In previous reports, we observed decreased levels of CREB protein and the active form of CREB (phosphoserine 133 CREB) in medial VSMC in rodent models of insulin-resistant and insulin-deficient diabetes. 6 Loss of VSMC CREB protein in this model was, in part, secondary to oxidant stress and could be modeled in vitro by exposure of aortic VSMC to H 2 O 2 or glucose oxidase. 6 Similarly, in a model of pulmonary vascular injury (hypoxia-induced pulmonary hypertension), we reported loss of CREB protein concurrent with pulmonary artery hypertrophy. 5 This could be modeled in vitro by exposing pulmonary VSMC to platelet-derived growth factor, which induced CREB nuclear export and degradation by a pathway downstream of Akt and casein kinase 2 (CK2).
In this article we report on the response of VSMC in vivo to rodent models of traditional cardiovascular risk factors, such as hyperlipidemia, hypertension, and obesity, and in vitro in the context of hyperlipidemia. We present data demonstrating loss of aortic CREB content across rodent models of elevated cardiovascular risk factors. For example, in an established model of atherosclerosis, LDL receptor-null (LDLR Ϫ/Ϫ ) mice exposed to high-fat diet, we observed a significant loss of CREB protein in the vascular media. These observations suggest that loss of CREB content and function is a common pathogenic VSMC response to cardiovascular risk factors. In additional studies in vitro, 24-to 48-hour exposure of VSMC to LDL and oxidized LDL (oxLDL) revealed CREB downregulation by only oxLDL through a mechanism involving generation of reactive oxygen species (ROS) and ERK activation, but independent of Akt, leading to nuclear exclusion. This suggests that CREB downregulation in VSMC may be induced by several mechanisms, including generation of ROS, which are likely to be important for the consistent loss of CREB observed in rodent models of elevated cardiovascular disease risk.
Materials and Methods
All materials and methods used standard techniques and commercially available reagents. Animal studies were conducted under AAALAC guidelines and were approved by individual Institutional Animal Care and Use Committees. Methods and statistical analysis were performed as previously reported and are outlined in detail in the Supplemental Materials and Methods (available online at http://atvb.ahajournals.org).
Results

Loss of CREB Protein in Aging and Hypertension
We previously reported decreased vascular CREB protein content in animal models of diabetes and pulmonary hypertension. 5, 6 We queried whether loss of vascular CREB was also observed across the spectrum of other conditions known to induce vascular pathology, including aging, hypertension, and dyslipidemia. Figure 1 demonstrates significantly decreased CREB content in aortic lysates with aging in C57/B6 mice (Jackson Labs, Bar Harbor, Me) and Sprague-Dawley rats (Charles River Laboratory, Wilmington, Mass) ( Figure  1A ). We next examined spontaneously hypertensive heart failure in rats. This rat model has a hypertension phenotype in the lean line and hypertension, insulin resistance, obesity, and glucose intolerance in the obese line. We observed a significant age-dependent loss of CREB protein that was more pronounced in the obese rats ( Figure 1B) , as observed in the insulin-resistant Zucker rat. 6
CREB Content Is Decreased in the Vasculature of High-Fat-Fed LDLR Knockout Mice
One of the best established models of rodent atherosclerosis is the LDLR Ϫ/Ϫ mouse that has a human pattern of dyslipidemia on a western diet. Aortic root sections were examined from 4 groups of animals (other results from this set of studies reported elsewhere 7 ): (1) C57BL/6 mice fed a chow diet; (2) C57BL/6 mice fed the high-fat western diet; (3) genetically hypercholesterolemic LDLR Ϫ/Ϫ mice fed a chow diet; and (4) LDLR Ϫ/Ϫ mice fed a western diet. Specimens were analyzed from 10 animals in each group. The data are presented as representative photos (Figure 2A ) and graphically as percent CREB-negative nuclei ( Figure 2B ). In the chow-fed animals, there was CREB staining in the majority of the nuclei of the medial VSMC in the aorta in control and LDLR Ϫ/Ϫ mice. The percentage of CREB-negative nuclei increased significantly in response to high-fat-feeding in both control and LDLR Ϫ/Ϫ mice (Figure 2A , B). Significant cholesterol elevation was only observed in the LDLR Ϫ/Ϫ mice. 7 In the LDLR Ϫ/Ϫ mice, cholesterol levels were 5-fold higher in the western diet group than in the chow group, and lipids correlated significantly with loss of nuclear CREB staining ( Figure 2C ). These data suggest that both high-fat diet and elevated cholesterol contribute to decreased nuclear CREB expression in aortic VSMC.
OxLDL Induces a Time-and Dose-Dependent Downregulation of Nuclear CREB Protein
Previous work from our group indicates that oxidative stress is a potent stimulus for CREB downregulation. 6, 8, 9 Published reports using LDL and modified LDL suggest that both directly increase VSMC oxidative stress. 10 We explored the effects of both LDL and oxLDL on VSMC CREB expression in vitro. Rat aortic VSMC were serum-depleted for 48 hours and then exposed to either LDL or oxLDL for 0 to 48 hours. We observed a significant reduction in CREB protein level within 24 to 48 hours of exposure to oxLDL, whereas native LDL did not affect CREB protein content ( Figure 3A ). Downregulation of CREB was dose-dependent, occurring at oxLDL doses of Ն25 g/mL after 24 hours of exposure ( Figure 3B ), but it occurred as early as 6 hours with higher oxLDL concentrations (data not shown). There was no significant change in CREB RNA ( Figure 3B ). Exposure of cells to oxLDL led to exclusion of CREB from the nucleus at 24 hours, whereas LDL-treated cells had preserved nuclear CREB content ( Figure 3E , F). Nuclear condensation was also observed at 24 hours with oxLDL only (data not shown).
LDL and OxLDL Activate CREB
Reports from our group and others 4, 6, 11 have demonstrated that an acute burst of oxidant stress activates numerous signaling pathways that activate CREB. We recently reported that free fatty acids acutely activate CREB via a protein kinase C-dependent, ROS/ERK-independent pathway. 12 Here, we examined CREB activation (phosphoserine 133 CREB) by LDL. In contrast to the differential effects of LDL and oxLDL on CREB content, both LDL and oxLDL led to an acute, transient activation of CREB ( Figure 3C ). CREB activation is dose-dependent, and doses as low as 10 g/mL of both LDL and oxLDL significantly and transiently increase CREB phosphorylation as early as 15 minutes ( Figure  3D ). Return of phosphoserine 133 CREB levels to normal after oxLDL treatment was somewhat variable and dependent on cell growth conditions and oxLDL potency (data not shown). CREB activation also correlates with induction of the known CREB-dependent gene, hemeoxygenase-1 (HO-1) ( Figure 5 ).
ROS and ERK Contribute to CREB Downregulation by oxLDL
To characterize the signaling events critical for oxLDLmediated CREB downregulation, we first assessed the signaling pathways activated in response to oxLDL. Consistent with previous reports in VSMC exposed to oxLDL, 10 we observed acute transient activation of 2 stress MAP kinases (ERK and p38 MAPK) as detected by Western blot analysis (Figure 4) , as well as a trend toward acute activation of another stress MAP kinase (JNK). In addition, we observe a modest activation of Akt. Both p38 MAPK and Akt activation are more persistent after oxLDL treatment than after LDL treatment. Our group recently reported that the mitogen/cytokine platelet-derived growth factor induces CREB nuclear export and degradation in pulmonary VSMC through persistent activation of Akt/CK2 and site-specific phosphorylation of CREB S103 and S107. 4 In earlier studies, we also reported ROS-mediated CREB downregulation. 6, 8, 9 To assess the importance of ROS activation of stress MAPK vs Akt/CK2 for CREB downregulation, we used studies in which primary rat VSMC were pretreated with a panel of pharmacological inhibitors or the ROS scavenger, N-acetylcysteine, before oxLDL exposure (Figure 5A ). Pharmacological inhibition of PI3K, Akt, p38 MAPK, and JNK had no significant effect on oxLDLmediated CREB downregulation ( Figure 5A ). Furthermore, experiments examining the Akt/CK2 pathway do not demonstrate induction of CK2 expression by either oxLDL or LDL (data not shown). Of interest, pharmacological inhibition of protein kinase A (H89), the original physiological activator of CREB, and protein kinase C (BIS), the mediator of fatty acid-induced CREB activation, 12 also did not block oxLDL-mediated CREB downregulation. Only scavenging of ROS (N-acetylcysteine) and inhibition of the ERK pathway (UO126) blocked CREB downregulation by oxLDL. In Figure 5B and 5C, we demonstrate that oxLDL-mediated CREB activation is also blocked by ROS scavenging and ERK inhibition, whereas induction of the CREB target gene HO-1 is inhibited only by the ROS scavenger N-acetylcysteine. In contrast, inhibition of ERK (UO126) increases basal HO-1 content, suggesting that the protective effect of ERK inhibition may occur through a preemptive induction of antioxidant pathways.
Antagonism of LDLR Does Not Interfere With oxLDL-Mediated CREB Degradation
To determine whether the oxLDL-mediated CREB degradation required the LDLR, cells were pretreated with antibodies to the LDLR (R&D Systems) for 30 minutes as outlined in Figure 6 . Acute CREB activation and later CREB downregulation and HO-1 induction by oxLDL were not prevented by pretreatment with anti-LDLR antibodies ( Figure 6 and data not shown), suggesting that these events do not require interaction with LDLR, consistent with a recent report by Hansen-Hagge. 13 
Discussion
Atherosclerosis is a complex process in which long-term exposure of the vessel wall to vascular insults induces the vicious cycle of vascular pathology. 1, 2 Regardless of the etiologic factor or factors, most atherosclerotic lesions share overlapping features, including endothelial dysfunction, neointimal proliferation, lipid accumulation, inflammation, and necrosis. 1, 2 Risk factors such as dyslipidemia, hypertension, diabetes, smoking, and age likely have both common and unique effects on the cellular and extracellular components of the vessel wall. We previously have reported 4 -6,8,9 that oxidant stress, mitogens, and cytokines lead to CREB downregulation in pulmonary and aortic VSMC, as well as in neurons and beta cells. Here, we present evidence that diminished aortic medial CREB expression is a common deleterious response to a variety of atherosclerotic risk factors. This series of experiments demonstrates significant age, hypertension, insulin resistance, and obesity-induced aortic VSMC CREB downregulation. Importantly, we directly demonstrate decreased aortic nuclear CREB expression in response to high-fat-feeding in both C57BL/6 and LDLR Ϫ/Ϫ mice. Furthermore, we demonstrate that in vitro exposure of rat primary VSMC to oxLDL leads to decreased CREB protein expression, specifically via a ROS/ERKdependent pathway. These data support a model wherein loss of VSMC CREB expression is a common pathological response to vascular injury, likely attributable to oxidant stress, which renders the vessel wall more susceptible to proliferation, migration, inflammation, and apoptosis, and potentially contributes to plaque progression. Others and we 4,14 -17,18 have reported that CREB is critical for oxidant defense and survival of VSMC, cardiac myocytes, neurons, and adipocytes. Cardiac-selective expression of dominant-negative CREB leads to accelerated heart failure and blocks the adaptive cardiac response to exercise training. 14, 19 In this context, cardiac CREB appears to regulate not only myocardial apoptosis but also metabolic adaptation by affecting mitochondrial biogenesis and efficiency. 17 We have further reported 8, 9 that overexpression of CREB in cultured neurons and beta cells can protect these cell types from oxidant and cytokine-mediated apoptosis. It seems likely that CREB plays a similar protective role in the vessel wall, where inflammation and oxidant stress accelerate atherosclerosis.
CREB protects cells from oxidant injury through transcriptional regulation of numerous targets, including genes involved in antiapoptotic mechanisms, upregulation of antioxidant defense, and augmentation of growth factor signaling. First, CREB inhibits apoptosis by stabilizing mitochondria through induction of bcl-2 and by augmenting mitochondrial biogenesis via peroxisome proliferator-activated receptor gamma coactivator-1␣ (PGC-1). In addition, oxidative stress leads to the induction of CREB-mediated antioxidant defenses on 2 levels, by inducing expression of antioxidant were loaded on all gels to allow gel to gel comparison, and blots of comparable exposure are shown. E, Representative Western blots are shown for HO-1. Blot portions shown were from the same experiment but from multiple gels as in (D). Note that inhibitor order is different from that shown in the graphs. Graphs represent data combined from 3 experiments, each with duplicate or triplicate independent samples. Because some experiments did not include all inhibitors, 3 to 7 independent samples are represented in each data point. Values are meanϮSD; P for comparison to corresponding control were calculated by ANOVA with Bonferroni correction for multiple comparisons. *PϽ0.05 vs corresponding no oxLDL control. Figure 6 . OxLDL-mediated CREB downregulation and HO-1 induction are not LDLR-dependent. Rat VSMC cells pretreated with or without LDLR-blocking antibody (5 g/mL) for 30 minutes and then exposed to oxLDL for 24 hours at the indicated doses. CREB is shown on top graph and HO-1 is shown on bottom graph. Bar heights represent means for independent duplicate samples, with error bars illustrating maximum values. Data shown are representative of 2 separate experiments, each performed with independent duplicate samples. One of the corresponding Western blots is shown below the graphs with a normalization control lane spliced out centrally. enzymes, such as manganese superoxide dismutase, thioredoxin, and HO-1 20 -22 and by increasing mitochondrial biogenesis via upregulation of PGC-1. Finally, CREB enhances appropriate growth factor signaling through regulation of brain-derived neurotrophic factor and insulin receptor substrate-2 (IRS)-2. 23, 24 Thus, loss of VSMC CREB function may contribute to disruption of vascular growth regulation and antioxidant and antiapoptotic defenses.
In this report, we demonstrate dramatic upregulation at the protein level of 1 antioxidant CREB target, HO-1, in response to oxLDL treatment. We hypothesize that this upregulation of HO-1 is, at least in part, a response to CREB activation and is 1 beneficial effect of CREB activation that could be lost with CREB downregulation. The persistence of HO-1 protein after CREB downregulation is not inconsistent with a CREB role in HO-1 activation, because the half-life of HO-1 mRNA is increased to up to 11 hours under certain types of oxidant stress. 25 However, HO-1 regulation is complex and multifactorial, involving many signaling pathways and transcription factors other than CREB, in addition to nontranscriptional regulatory mechanisms. 26, 27 Overall, the HO-1 activation we demonstrate is a marker of severe oxidant stress imposed by oxLDL treatment, and our studies do not rule out a role for other regulatory pathways. In fact, the oxLDL resistance inferred by ERK inhibition with UO126 may be the result of early HO-1 activation and represent a preconditioning that allows cells to cope with the oxidant stress imposed by oxLDL.
The hypothesis that CREB downregulation contributes to vascular pathology in atherosclerosis implies that CREB activity is important for maintaining normal vascular physiology. CREB is a differentiation factor in VSMC, but the function of CREB in normal physiology is not as clearly delineated in the vasculature as it is in the nervous system. 28, 29 Acute CREB activation by a broad array of toxins may be a cytoprotective response to injury. 18 Recently, a number of observations have been published demonstrating acute CREB activation by established mediators of vascular injury, such as fatty acids, LDL cholesterol, very low density lipoprotein cholesterol, thrombin, endothelin-1, angiotensin II, and tumor necrosis factor-␣ in endothelial cells and VSMC, both in vitro and in vivo 11,30 -35 We postulate that acute CREB activation by vascular toxins is a healthy response that is intended to decrease oxidant injury and inflammation and maintain VSMC survival and function. However, we acknowledge that there are conflicting data on the role of CREB in acute vascular injury. CREB activity was found to be increased in carotid arteries after wire injury. 36 Introduction of a dominant-negative CREB adenovirus at the time of wire injury blunted neointimal lesion formation and led to increased VSMC apoptosis and decreased proliferation. 36 The explanation for these differences from our studies of CREB and VSMC phenotype remains unclear. They are likely dependent on intracellular pathway activation profiles and coadaptor/corepressor recruitment to CREB target genes that are unique depending on the external stimulus and cell context. [37] [38] [39] [40] The mechanism of CREB downregulation in the vasculature also remains unclear. Numerous mechanisms have been shown to contribute to the CREB dysfunction observed in Alzheimer disease, human immunodeficiency virus, cocaine addiction, and pulmonary hypertension. 4, 34, [41] [42] [43] [44] [45] [46] [47] It is likely that decreased vascular CREB content across the different rodent models presented in this article is also the consequence of multiple mechanisms. First, CREB is a self-regulating protein, such that loss of upstream signaling to CREB can result in decreased CREB expression. For example, depletion of cyclic nucleotides and decreased protein kinase A/protein kinase G activation decreases CREB expression. 48, 49 The loss of endothelial nitric oxide synthase-stimulated cyclic nucleotide accumulation in endothelial dysfunction results could thus contribute to decreased vascular CREB expression. Another mechanism is suggested by our previous finding that platelet-derived growth factor induces an Akt/CK2-mediated ubiquitination and degradation of CREB in pulmonary VSMC. 4 Since expression of platelet-derived growth factor and its receptor are increased in models of atherosclerosis, this mechanism could also occur in the systemic vasculature. It is probable that generation of ROS is the major underlying contributor to CREB downregulation across vascular disease models. ROS have been shown to disrupt signaling to CREB 9 and to promote CREB degradation in Alzheimer disease. 47 We have reported downregulation of CREB in aortic VSMC, neurons, and beta cells in response to direct oxidant stress. 4, 6, 8, 9 In further support of this hypothesis, we now report that the potent cardiovascular risk factor, oxLDL, directly induces CREB downregulation in VSMC in vitro. In cell culture, simple screening with pharmacological inhibitors indicates that generation of ROS and activation of ERK, but not protein kinase A or Akt, are critical for oxLDL-mediated loss of CREB expression. Another recent report 10 has also suggested that induction of oxidant defense can block effects of LDL on VSMC. A more exhaustive series of studies will be needed to fully define the oxidant-induced signaling pathways important for CREB downregulation.
Loss of vascular medial CREB expression appears to be an early response of the vessel wall to cardiovascular risk exposure; as such, interventions aimed at restoring or maintaining vascular CREB are an appealing goal. Lifestyle interventions demonstrated to improve longevity and decrease cardiovascular risk also increase CREB function. 52, 53 In the central nervous system, exercise training enhances neural nitric oxide synthase expression, leading to induction of CREB. 18, 54 Furthermore, exercise increases active CREB and contributes to improved recovery from ischemia, stroke, and memory tasks after seizure. 52, 55 Preliminary observations indicate that age-related decrease in aortic CREB protein content can be abrogated by caloric restriction (Reusch et al, unpublished observations 2009). Watson et al 17 also recently reported increased cardiac CREB content with modest exercise training in a rodent model of heart failure. Unfortunately, the compensation for VSMC CREB deficiency is not as easy as adding CREB to the vessel wall, because inflammatory cell differentiation also uses CREB (lumen in Figure 2 ). Thus, interventions aimed at restoring CREB likely will need to be directed at the underlying mechanisms of CREB loss and will require a better understanding of these mechanisms. Interestingly, thiazolidinediones, agents that increase insulin sensi-tivity have also been found to increase CREB content in the heart and blood vessels of the insulin-resistant ob/ob mouse model 6 (Reusch, unpublished observations). In an Alzheimer disease model, blocking CREB degradation with an inhibitor of ubiquitin 1 ligase led to increased CREB expression and improved cognition. 43 Overall, clarification of the mechanisms of CREB loss in vascular disease may suggest novel therapeutic targets for vascular intervention and augmentation of CREB-dependent vascular defenses.
Conclusion
In summary, we report loss of CREB expression across a spectrum of rodent models of vascular risk, including insulin resistance, aging, and high-fat diet. The relevance of oxLDL to the in vivo vascular CREB depletion model is supported by the loss of CREB on direct challenge of VSMC with oxLDL in vitro. Simple analysis of critical pathways reveals that blockade of ROS generation or ERK activation protects cells from CREB depletion and from oxLDL toxicity. This in vitro model will allow further analysis of the mechanism of oxLDL-mediated CREB loss in VSMC. These experiments provide new information on a common response to vascular injury that may be an early event in atherosclerosis and is a potential new target for cardiovascular disease intervention.
